CIRM’s governing board awarded $14.5 million to advance three promising cancer therapies toward clinical testing.
All three projects use CAR-based cell therapy. This approach modifies a patient’s immune cells to recognize and destroy cancer cells.
Moving Therapies Toward Patients
The awards support translational-stage research projects through CIRM’s TRAN1 program.
These projects focus on early development activities. Those activities can help move potential therapies into clinical studies or broader use.
Researchers use this stage to address important questions before testing treatments in larger clinical trials.
Reprogramming the Immune System
Each project uses a form of CAR-based cell therapy.
The approach begins with T cells, immune cells that can destroy abnormal or foreign cells. Researchers modify these cells by adding a chimeric antigen receptor, or CAR.
The CAR helps the engineered cells recognize specific signals on cancer cells. Once they identify those signals, the cells can attack and destroy the tumor.
Three Projects, One Approach
The three projects target different areas of cancer research. However, they share the same basic strategy: use engineered immune cells to fight cancer.
The funding will help each research team complete the work needed to advance its potential therapy.
In the sections below, we take a closer look at the three newly approved projects.
UCSF Team Develops CAR-T Therapy for Glioblastoma

CIRM awarded $2.66 million to the University of California, San Francisco (UCSF). The funding will support a CAR-T therapy for glioblastoma.
Glioblastoma is an aggressive cancer that develops in the brain and spinal cord. The disease remains difficult to treat, creating a need for new therapeutic approaches.
Targeting Two Tumor Signals
Hideho Okada, M.D., Ph.D., and his UCSF team developed specialized CAR-T cells. The cells can recognize two signals found on glioblastoma tumor cells.
After identifying those signals, the CAR-T cells could attack and destroy the cancer cells.
Targeting two signals may help the engineered cells recognize glioblastoma more effectively.
Testing the Therapy in Mice
The researchers will test the therapy in mice with human glioblastoma grafts.
They will evaluate the treatment’s preclinical safety. They will also determine whether the CAR-T cells produce the intended anti-tumor response.
The results could help the team decide whether the therapy is ready for further development.
UCLA Team Develops CAR-iNKT Therapy for Multiple Myeloma

CIRM awarded $5.95 million to the University of California, Los Angeles (UCLA). The funding will support a potential cell therapy for multiple myeloma.
Multiple myeloma is a blood cancer. The UCLA team will develop engineered immune cells that can target and attack multiple myeloma tumors.
Creating Cells From Blood Stem Cells
Lili Yang, Ph.D., and her team developed a method to create invariant natural killer T, or iNKT, cells.
The researchers start with human blood stem cells. They use these cells to produce iNKT cells, a specialized type of T cell.
iNKT cells can attack tumors through several different mechanisms. They can also migrate to and infiltrate tumor sites.
Adding a Cancer-Targeting Receptor
The researchers modify the iNKT cells with a chimeric antigen receptor, or CAR.
The CAR enables the new CAR-iNKT cells to recognize a specific signal found on multiple myeloma cells. The engineered cells could then target and destroy the cancer.
Testing the Therapy in Mice
The team will test the therapy in mice with human multiple myeloma tumors.
Researchers will evaluate the treatment’s preclinical safety. They will also determine whether the CAR-iNKT cells produce the intended anti-tumor response.
These studies could provide important data for the therapy’s continued development.
TRAN1-12258

Another $5,904,462 was awarded to UCLA to develop specialized CAR-T cells to treat melanoma, a form of skin cancer. Cristina Puig-Saus, Ph.D. and her team will use naïve/memory progenitor T cells (TNM), a subset of T cells enriched with stem cells and memory T cells, an immune cell that remains long after an infection has been eliminated. After modification with CAR, the newly created CAR-TNM cells will target a specific signal present in melanoma. The team will test the therapy in mice with human melanoma. They will be looking at preclinical safety and if the CAR-TNM cells are able to produce a desired or intended result.
